期刊文献+

乳腺癌p53和c-erbB-2基因表达与腋淋巴结转移的相关性分析 被引量:3

Relation between axillary node metastasis and the expression of c-erbB-2 and p53 in breast cancer
暂未订购
导出
摘要 目的 :通过免疫组化方法检测乳腺癌患者 p5 3和c erbB 2基因表达 ,分析其与腋淋巴结转移的相关性。 方法 :乳腺癌患者 6 7例 ,均行改良根治术。标本常规石蜡包埋切片 ,苏木精 伊红 (H E)染色 ,计算淋巴结总数和阳性淋巴结数 ;同时取乳腺癌组织石蜡切片行c erbB 2和 p5 3免疫组化染色 ,阳性判断按癌细胞染色细胞的百分率计算 ,不染色为阴性 ;<2 5 %为 (+) ;2 5 %~ 5 0 %为 (2 +) ;>5 0 %为 (3+)。 结果 :所有患者均经常规病理证实为乳腺导管癌 ,淋巴结转移阴性者 31例 ,占 4 6 % ,阳性者 36例 ,占 5 4 %。 p5 3阳性者占 5 6 % ,淋巴结转移阳性者p5 3阳性率低于阴性者 ,但差异无显著性意义。淋巴结转移阳性者c erbB 2阳性率高于阴性者 ,但差异无显著性意义。p5 3和c erbB 2同时阳性者有淋巴结转移者例数明显多于两者同时阴性及单独阳性者 (P <0 .0 5 )。 结论 :p5 3和c erbB 2在乳腺癌患者有比较高的阳性表达 ,两者单独阳性与腋淋巴结转移相关性无显著性意义 。 Objective:To study the relation between axillary node metastasis and the expression of c-erbB-2 and p53. Methods:Among 67 breast cancer (NNBC) patients with the modify radical mastectmoy, c-erbB-2 and p53 oncogenes were identified prospectively using immunohistochemical staining. The axillary node metastasis was examined. Furthermore, the possible relation between axillary node metastasis and the expression of c-erbB-2 and p53 were investigated. Results:The prevalence rates for staining of p53 were 56.4%. By univariate analysis, the expressions of c-erbB-2 and p53 were associated significantly in patients with the axillary node metastasis. Conclusion:The simultaneously expressions of c-erbB-2 and p53 appear to be the strong marker for predicting the axillary node metastasis.
出处 《医学研究生学报》 CAS 2004年第10期884-886,共3页 Journal of Medical Postgraduates
关键词 乳腺癌 P53 c—erbB-2 腋淋巴结转移 Breast cancer c-erbB-2 p53 Axillary node metastasis
  • 相关文献

参考文献9

  • 1Slamon DF,Clark GM,Wong SG et al.Human breast cancer: correlation of relapse and suruival with amplification of the her-2/neu ncogene[].Science.1987
  • 2Yakes FM,Chinratanalab W,Ritter CA et al.Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is reqired for antibody-mediated effects on p27 , cyclin D1, and antitumor action[].Cancer Research.2002
  • 3Mazars R,Spinardi L,BenCheikh M et al.p53 mutations occur in aggressive breast cancer[].Cancer Research.1992
  • 4Archre SG,Elipoulos A,Spandidos D et al.Expression of ras ,p21, and c-erbab-2 in advanced breast cacer and response to first line hormonal therapy[].British Journal of Cancer.1995
  • 5Sigrid S.The p53 gene in breast cancer prognostic value of complementary DNA sequencing versue immnuohistochemistry[].Journal of the National Cancer Institute.1996
  • 6Pharaoh PD,Day NE,Caldas C.Somatic mutations in the p53gene and prognosis in breast cancer: a meta-analysis[].British Journal of Cancer.1999
  • 7Aas T,Borresen AL,Geisler S et al.Specific p53 mutations areassociated with de novo resistance to doxorubicin in breastcancer patients[].Nature Medicine.1996
  • 8Kandioler-Eckersberger D,Ludwig C,Rudas M et al.TP53 mutation and p53 overexpressionfor prediction of response to neoadjuvant treatment in breastcancer patients[].Clinical Cancer Research.2000
  • 9Nakopolou LI,Alexiadou A.Prognostic significance of the coexpression of p53 and c-erbB-2 proteins in breast cancer[].Journal of Paleopathology.1996

同被引文献30

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部